back to
back to

Program: Saturday (12.10.2013)

08:30 – 13:45

Room: Pipin II
(Dorint Hotel)

Hematology Educational Hematology Educational

  • Chronic Lymphocytic Leukemia (CLL)

    • Michael Hallek

  • Mantle Cell Lymphoma (MCL)

    • Martin Dreyling

  • Follicular Lymphoma (FL)

    • Eva Kimby

  • Aggressive Non-Hodgkin-Lymphoma (NHL)

    • Michael Pfreundschuh

  • Multiple Myeloma (MM)

    • Meletios-Athanassios Dimopoulos

  • Chronic Myeloid Leukemia (CML)

    • Paul La Rosee

10:00 – 11:30

Room: Pipin II
(Dorint Hotel)

Workshop Prognostic and biomarkers – tissue and serum / plasma

  • Christian Steidl

  • The immunomodulatory and angiogenic protein Galectin 1 is a circulating biomarker in Hodgkin Lymphoma

    • Margaret Shipp

  • Plasma TARC as a treatment response marker and prognostic tissue biomarkers in classical Hodgkin Lymphoma

    • Arjan Diepstra

  • Prognostic biomarkers from gene expression pro ling in formalin- xed para n-embedded biopsies

    • Christian Steidl

  • Flow cytometry studies of lymphocyte predominant cells from nodular Lymphocyte Predominant Hodgkin Lymphoma

    • Jonathan Fromm

  • Identication of CD8 ‘follicularcytotoxic’ cells in tumor infiltrating T cells from classical Hodgkin Lymphoma

    • Luc Xerri

10:00 – 11:30

Room: Sandkaul
(Dorint Hotel)

Workshop Closed workshop for pediatric groups

  • Judith Landman-Parker
  • Monika Metzger

  • Overview of international harmonization of staging and response criteria in pediatric Hodgkin Lymphoma – summary of results thus far

    • Monika Metzger

  • Highlights and controversies found between existing major pediatric groups

    • David Hodgson

  • Discussion

    • Judith Landman-Parker

12:00 – 13:30

Room: Martin & Augustin
(Dorint Hotel)

Workshop GHSG Workshop

  • Andreas Engert
  • Michael Fuchs

12:00 – 13:30

Room: Pipin II
(Dorint Hotel)

Workshop Radiotherapy of Hodgkin Lymphoma in 2013

  • Tim Illidge
  • Lena Specht

  • New concepts of eld and dose: Implications for disease control and long-term outcome

    • Lena Specht

  • The role of radiotherapy in early stage and the relevance of PET response

    • Tim Illidge

  • Is radiotherapy still relevant for patients with advanced stage disease and in salvage of chemotherapy failures?

    • Joachim Yahalom

12:00 – 13:30

Room: Severin
(Dorint Hotel)

Workshop Challenges in the development of new drugs in HL

  • Peter Borchmann
  • Anas Younes

  • Progress on new drug development in Hodgkin Lymphoma

    • Alison Moskowitz

  • Clinical trials design, response assessment, and trial end points

    • Anas Younes

  • Challenges of translation of abundant new data into clinical trials in rare diseases

    • Peter Borchmann

  • Challenges of preclinical models

    • Bastian von Tresckow

14:00 – 15:30

Room: Pipin II
(Dorint Hotel)

Workshop New technologies for improving the therapeutic ratio of RT in HL

  • George Mikhaeel
  • Joachim Yahalom

  • Optimizing and using imaging for RT planning

    • George Mikhaeel

  • Advanced conformal RT for reduction of normal organ exposure

    • Umberto Ricardi

  • Techniques for reduction of breast exposure

    • Bouthaina Dabaja

  • Breath-hold techniques

    • Peter Meidahl Petersen

  • Proton therapy for Hodgkin Lymphoma

    • Richard Hoppe

  • Early detection of breast cancer

    • Andrea Ng

14:00 – 15:30

Room: Pipin I
(Dorint Hotel)

Workshop PET

  • Martin Hutchings
  • Alison Moskowitz

  • The new NCCN guidelines and the role of PET / CT

    • Craig H. Moskowitz

  • Imaging and PET / CT recommendations for the revised staging and response criteria

    • Martin Hutchings

  • Metabolic tumor volume and other new concepts

    • Lawrence H. Schwartz

  • qPET – a quantitative approach to assess response in interim FDG-PET scans in lymphoma

    • Dirk Hasenclever

14:00 – 15:30

Room: Severin
(Dorint Hotel)

Workshop Somatic aberrations, epigenetic mechanisms and deregulated gene expression

  • Randy Gascoyne
  • Wolfram Klapper

  • Novel and recurrent coding sequence mutations in microdissected Hodgkin-/ Reed- Sternberg cells

    • Christian Steidl

  • No chance for a comeback? The multiple ways to block the B-cell phenotype in Hodgkin Lymphoma

    • Michael Hummel

  • New insights into the transcription factor network of Hodgkin-/ Reed-Sternberg cells

    • Stephan Mathas

  • Transcriptome analysis of Hodgkin and Reed-Sternberg cells enriched from Hodgkin Lymphoma biopsies: an approach to virus discovery

    • Ruth Jarrett

  • Downregulation of FOXO1 prevents induction of the tumor suppressor PRDM1 in cHL

    • Martin Vogelhuber

16:00 – 17:30

Room: Pipin I
(Dorint Hotel)

Workshop Integrating PET into the management of early stage HL

  • Andreas Engert
  • John Radford

  • Introduction

    • Andreas Engert

  • RAPID trial: Update and lessons in standardized interpretation of PET

    • John Radford

  • BCCA experience: Population-based PET guided treatment

    • Richard Klasa

  • Challenges applying PET for early stage disease

    • Martin Hutchings

  • What did EORTC H10 teach us?

    • Massimo Federico

  • Formulation of conclusions and identi cation of important outstanding questions

    • John Radford

16:00 – 17:30

Room: Martin & Augustin
(Dorint Hotel)

Workshop International Guidelines on Follow-up and Survivorship

  • Bruce Cheson
  • John Raemaekers

  • Some “philosophical” introductoryremarkson the need and pitfalls of long-term follow-up

    • Alexander Fosså

  • The ASCO and the Dutch guidelines

    • Nicky Dekker

  • Minimizing treatment and its consequences for long term toxicity and follow-up

    • John Radford

  • Reducing RT to involved node principle and its consequences for long-term toxicity and follow-up

    • David Hodgson

  • General discussion

16:00 – 17:30

Room: Severin
(Dorint Hotel)

Workshop Genetic predisposition – HLA, GWAS, secondary malignancies, prognostic

  • Kari Hemminki
  • Andreas Rosenwald

  • Familial risks and germline genetics of Hodgkin Lymphoma

    • Kari Hemminki

  • HLA locus and risk of Hodgkin Lymphoma

    • Hauke Thomsen

  • Multiple neoplasias a er Hodgkin Lymphoma; incidence and risk factors

    • Berthe Aleman

  • Genetic defects of T-cell function predisposing for EBV-associated lymphoproliferation and Hodgkin Lymphoma

    • Kirsten Bienemann

  • General discussion

18:00 – 19:00

Room: Pipin I
(Dorint Hotel)

Workshop Targeted Therapy: The Future in the Treatment of Malignant Lymphoma

  • Peter Borchmann

  • New approaches in the treatment of mantle cell and other Non Hodgkin Lymphoma

    • Anas Younes

  • New horizons in the treatment o CLL

    • Michael Hallek

Archive

You a viewing the program of a past symposium. Click here to get back to the current conference.